top of page

Aulos Bioscience CEO Aron Knickerbocker discusses his company's antibody approach to IL-2 at #ASCO24

Aron Knickerbocker describes the benefits of focusing on the CD-25 binding portion of IL-2 and discusses some data presented at ASCO. He believes this program is the first AI designed human antibody to enter the clinic.


Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight


Breakthrough Properties is a life science real estate company that is exclusively focused on delivering cutting-edge environments for the life science industry. With a portfolio of roughly 5 million square feet across the US, UK and continental Europe, Breakthrough has emerged as a leading partner for high-growth biotechs and pharmas around the world. 

bottom of page